The pathogenesis of sepsis begins with the proliferation of micro-organisms at a site of infection, followed by invasion of the bloodstream and other organs. Gram-negative bacteria account for a large part of sepsis cases. The structural component of Gram-negative bacteria, endotoxin or lipopolysaccharide (LPS), induces the synthesis and release of endogenous mediators of sepsis. A growing number of investigations of the molecular mechanisms occurring in sepsis, point to endotoxin as a central mediator leading to multi-organ failure and death. In numerous clinical trials, attempts to target molecules downstream of endotoxin have been made, but have not been associated with improved survival. We describe an affinity-based system for the selective removal of endotoxin from plasma. The small-scale device, a 1.5 ml cartridge, contains beads that bind endotoxin with high specificity and efficiency. In addition, evidence is presented that this device does not affect plasma hemostasis, nor does it activate the complement system. Taken together, these results represent a proof of principle for endotoxin removal from plasma, which may be of clinical value to treat sepsis by extracorporeal circulation of the blood through a scaled-up version of this endotoxin-removing device.
INTRODUCTION
Currently, the leading cause of death in intensive care units (ICUs) is multiple organ failure (MOF). In the etiology of MOF, the frequency of infection, sepsis, and inflammation is very high. In spite of the fact that more and more different kinds of antibiotics are reaching the pharmaceutical market, and are widely used in the treatment of sepsis, death from septic shock in the US is continually increasing (35,000 in 1970 to 198,000 in 1990) . The death rate from septic shock has been on the rise from 1.7 to 7.9 per 100,000 people. There are approximately 750,000 patients suffering from this condition annually in the US only. About 250,000 of these will die as there is no specific treatment currently available for this severe illness. 1 The treatment of sepsis has proved to be difficult, expensive and, so far, an unrewarding task. None of the newer therapeutic modalities for sepsis suggested in the last decade, including treatments with antibodies (anti-TNF-a), soluble receptors and antagonists of one or another mediator (IL-1R, PAF, bradykinin, prostaglandin), has led to improved survival in large-scale clinical trials. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] For now, the standard treatments of septic shock are urgent stabilization of the patient, volume resuscitation, vasopressors and/or inotropic therapy to restore perfusion, and the administration of broad spectrum, empirical antibiotic therapy in the setting of an ICU. The fact that efficient antibiotics may increase the release of endotoxin in the circulation due to bacterial killing deserves some consideration. This phenomenon may be associated with further deterioration of the clinical status of septic patients. 12, 13 Dotrecogin a-activated/activated protein C, used in a phase III multicenter clinical trial, resulted in a 6.1% reduction in the absolute risk of death. 14 With the emergence of this promising approach, the need for additional therapeutic options still remains important.
The need for investigating the specific removal of substances implicated in septic shock, particularly endotoxin, has been recognized. [15] [16] [17] Indeed, the structural component of Gram-negative bacteria, endotoxin, plays a pivotal role in the initiation and development of the sepsis syndrome by inducing the synthesis of various proinflammatory and anti-inflammatory compounds. [18] [19] [20] [21] [22] [23] [24] In Gram-negative septicemia, the role of endotoxin in eliciting the multiple abnormalities of the coagulation system has also been documented. [25] [26] [27] [28] [29] High endotoxin levels are consistently measured in the blood of patients with severe septic shock syndrome. It appears that the clinical picture correlates with the level of endotoxin in the blood of the patients. 15, 30, 31 Endotoxin levels were found to be higher in non-survivors versus survivors, and inversely proportional to the length of survival. 30 However, this finding has not been reproduced across all studies. When adjusting for severity of illness, Bates et al. 32 found no correlation between Limulus amebocyte lysis (LAL) positive assay and mortality. Rather, an endotoxin-cytokine score was correlated with survival in sepsis. 33 It is also of interest that the presence of high levels of circulating endotoxin seems to be independent of the causative micro-organism responsible for sepsis. In the case of Gram-positive bacteria or fungus-mediated sepsis, translocation of Gram-negative bacteria and subsequently of endotoxin from the gut into the circulation, may also contribute to the development of septic shock. 15, 30, 34 A beneficial effect of endotoxin removal in septic shock has been previously demonstrated using direct hemoperfusion through polymyxin B immobilized onto polystyrene fibers (PMXF). [35] [36] [37] Adsorption of endotoxin by using PMXF led to a reduction of endothelin-1, 38 supporting the notion that removing endotoxin could have an impact on reducing endothelin-1-mediated organ damage. An antibody against the LPS receptor CD14 provided therapeutic benefit after exposure of rabbits to endotoxin. 39 An anti-CD14 also influenced coagulation and fibrinolysis responses during endotoxemia in humans. 16 This paper reports an efficient and specific method to remove endotoxin from plasma. Ofloxacin has not been previously identified as an endotoxin ligand, but has been shown to inhibit LPS-induced production of TNFa and IL-6 by peripheral blood mononuclear cells in vitro. Amongst various antimicrobial agents, only Ofloxacin showed inhibitory activity against IL-6 production, one interpretation for which could be a specific interaction with endotoxin. 40 Nevertheless, the mechanism responsible for this effect has not been elucidated. Ofloxacin presents three tertiary amines that confer a positive charge to the molecule, available to interact with the negatively charged phosphate groups of endotoxin. In addition, the presence of two condensed rings confers hydrophobic properties enhanced with a fluorine substitution. This may allow for hydrophobic interactions with the acyl chains of the lipid A portion of endotoxin. Through empirical investigation, Ofloxacin was found to be an efficient ligand for endotoxin from various bacterial sources. Contact of plasma with the affinity resin did not affect plasma hemostasis as indicated by no activation of coagulation, no consumption of coagulation factors and no change in fibrinogen concentration. In addition, there was no evidence of complement activation. Therefore, this technology may be clinically applicable to treat septic shock.
MATERIALS AND METHODS

Preparation of affinity resins
Epoxy-activated highly crosslinked agarose beads (size range 100-200 mm; Sterogene Bioseparations, Carlsbad, CA, USA) were used to immobilize the endotoxin-binding ligand Ofloxacin (Sigma, St Louis, MO, USA) at 30 mg/ml, following the directions of the manufacturer.
Polymyxin B (PMXB) was immobilized on agarosebased activated beads Actigel (Sterogene Bioseparations), according to manufacturer's instructions. Typical amounts of immobilized ligand were 40 mM for Ofloxacin and 36 mM for PMXB. Epoxy-activated highly crosslinked agarose beads (Sterogene Bioseparations) were used as a negative control.
Preparation of Pseudomonas maltophilia and
Escherichia coli culture supernatants P. maltophilia and E. coli O55:B5 were obtained from ATCC (Rockville, MD, USA) and the bacterial culture broth from Difco Laboratories (Detroit, MI, USA). Cultures were grown at 37°C, and LPS in the supernatant was monitored periodically by the LAL assay (sensitivity, 0.005 EU/ml with the E. coli O55:B5 endotoxin from Charles River, Charleston, SC, USA). The total culture time was 48 h. Then the culture was refrigerated at 4°C and centrifuged at 2000 g. The supernatant was sterile filtered and aliquoted for frozen storage. In some experiments, 20 mg/ml gentamycin (Sigma) and 5 mg/ml ciprofloxin (Bayer, West Haven, CT, USA) were added to the supernatant. Similar results for the LAL assay or the removal of endotoxin on the resin were found in the absence or presence of these antibiotics. The sterility of the filtrate was ascertained using agarplate culture; no colony growth was observed. The LPS concentration in the culture supernatant was 80,000 EU/ml for P. maltophilia and 200,000 EU/ml for E. coli.
Preparation of plasma
Heparinized plasma was either purchased from Bioresource Technologies (Fort Lauderdale, FL, USA) or prepared from blood from healthy volunteers. Plasma was prepared by spinning the whole blood at 1800 g for 20 min at 12°C. The resulting supernatant was sterile filtered with a 0.22 mm filter.
Dynamic circulation of plasma through the endotoxinremoving column A 1.5 ml glass column was pretreated with Sigmacoat (Sigma) in order to remove negative charges on the surface of the glass, which would induce the intrinsic coagulation pathway. The glass column was then packed with resin. The column was decontaminated using 1 M NaOH as follows. At 3 ml/min, 1 M NaOH (25 ml) was pumped through the column and was allowed to sit in the column overnight. The next day, the column and the tubing were rinsed to neutrality with endotoxin-free LAL water (Charles River). Sample ports were also decontaminated with 1 M NaOH overnight and rinsed under sterile conditions with LAL water, before being placed at the inlet and outlet of the column. For coagulation studies involving prothrombin time (PT) and activated partial thromboplastin time (APTT), sodium citrate (10 mM) was used as an anticoagulant. For fibrinogen concentration or thrombin-antithrombin (TAT) assays, heparin or citrate was used.
Plasma was spiked with 1-5 EU/ml of endotoxin from P. maltophilia or E. coli O55:B5 supernatant or reconstituted purified endotoxin. Purified endotoxin from E. coli O55:B5 or Pseudomonas aeruginosa and Salmonella typhimurium (both from Sigma) were reconstituted in LAL water and vortexed. After spiking with endotoxin, the plasma was incubated for 30 min at room temperature. The tubing placed upstream of the column was emptied of LAL water and primed with plasma to be run on the column. The plasma was then run through the column at a flow rate of 0.6 ml/min using a peristaltic pump. This flow rate was adopted for small-scale experiments on the basis of the flow rate used in clinical plasmapheresis (60-100 ml/min) and an estimated prospective 150 ml clinical size device. Plasma was not collected until 3.5 min to eliminate dilution with LAL water present in the 1.5 ml column.
Samples were taken at regular intervals via the sample ports placed upstream and downstream of the column using sterile needles and syringes, or a single pre-col-umn sample was obtained from the plasma loaded onto the column.
Endotoxin measurement by the Limulus amebocyte lysate assay
The amount of endotoxin was measured in pre-and postcolumn plasma samples by the LAL kinetic turbidimetric assay (Charles River). This assay was first validated for endotoxin measurement and comparisons in pre-and post-column plasma samples. Unspiked plasma was run through the column and pre-and post-column plasma collected. Known amounts of endotoxin (0.5, 1, 2 and 5 EU/ml) from P. maltophilia or E. coli culture supernatants, or purified E. coli, S. typhimurium, or P. aeruginosa were added in water, pre-column plasma and post-column plasma, and measured by the LAL assay. The assay was performed under a laminar flow hood. Spiked heparinized plasma samples were then diluted 10 times. In some experiments, spiked plasma samples were diluted 67 times where specified in the Results section. All samples were then heat-inactivated at 75°C for 15 min, and vortexed for 2 min. A 1:10 dilution and heat-inactivation removed the inhibitory activity on the LAL assay of 90% of the plasma samples tested. This is in agreement with the wide range of LPS-neutralizing capabilities measured in plasma, partly mediated by the endotoxin binding proteins such as LPS binding protein, lipoproteins, particularly high-density lipoproteins. 20, 41 The 10% of plasma samples with strong inhibitory effect on LPS activity that was not removed by a 1:10 dilution and heat inactivation were not used in our study. A 5.0-0.005 EU/ml standard curve was prepared with an Endosafe ® certified control standard endotoxin prepared from E. coli O55:B5. Samples were loaded onto 96-well plates. Each sample was processed in duplicate. The LAL lysate was added to initiate the reaction. Turbidity was read for 1 h at 37°C in a Bio-Tek Elx808 microplate reader. Measurements were made automatically every minute throughout the LAL reaction period. Data were transferred and analyzed using the Biolise Software. Standard curve correlation coefficients were at least -0.98. The coefficient of variation of the standards and samples were between 0-10%.
Preparation of human monocytes and endotoxin challenge
Monocytes were prepared by Ficoll separation of peripheral blood, and removal of non-adherent cells as follows. The mononuclear cells were incubated at 37°C in a CO 2 incubator at a density of 10 6 cells/well in 6-well plates, overnight in RPMI-1640 medium (Irvine Scientific, Santa Ana, CA, USA) containing 100 U/ml penicillin/ streptomycin and 2 mM glutamine supplemented with 20% FCS. Adherent cells were then incubated in 0.75 ml RPMI-1640 (2x) containing 6% FCS and 0.75 ml of tested samples. Each sample was tested in duplicate culture wells. This assay was first validated for comparisons of the TNF-a inducing effects of pre-and post-column plasma samples. This was done by comparing TNF-a production induced by pre-and post-column plasma spiked with known amounts (0, 10, 50, 200 EU/ml) of P. maltophilia endotoxin after the post-column plasma was obtained from running unspiked plasma through the column. The same amounts of endotoxin in water were also used to treat monocytes. For assessment of P. maltophilia endotoxin removal by the resin, citrated plasma spiked with 200 EU/ml was run through the resin, and samples of post-adsorption resin collected at various times were tested. Non-treated cells (supplemented with 0.75 ml unspiked plasma) were used for baseline TNF-a production, which was subtracted from each sample value. TNF-a was measured from the culture supernatant after 24 h incubation.
TNF-a measurement
For this assay, the TNF-a sandwich ELISA kit from Cell Sciences (Norwood, MA, USA) was used. The kit contains a 96-well microtiter plate with immobilized anti-TNF-a, TNF-a standards, antibody and peroxidase substrate. The absorbance was measured at 450 nm. The assay was performed following the manufacturer's instructions. Each sample was tested in duplicate.
Coagulation assays
Thrombin-antithrombin complex (TAT) measurement
In order to assess the possibility of activation of coagulation, pre-and post-column plasma samples were assayed for TAT complexes by ELISA (Enzyme Research Lab, South Bend, IN, USA). Samples were diluted with TATpoor plasma obtained from a normal donor in 3.8% citrate.
Prothrombin time (PT) and activated partial prothromboplastin time (APTT) measurements
The possible consumption of coagulation factors was assessed by PT and APTT assays. PT assay was performed by incubating 50 ml of plasma at 37°C for 3 min. Then, 100 ml of Innovin-recombinant human tissue factor thromboplastin (Baxter Diagnostics Inc., Deerfield, IL, USA), prewarmed at 37°C was added to initiate clotting. APTT assay was performed by incubating 50 ml of plasma and 50 ml of APTT reagent (Organon Teknika, Durham, NC, USA) at 37°C for 5 min. Then, 50 ml of 25 mM CaCl 2 pre-warmed at 37°C was added to initiate clotting.
Fibrinogen concentration
Fibrinogen concentration was measured using the enzyme Atroxin (Sigma), which catalyzes the formation of fibrin from fibrinogen and is insensitive to heparin, thus allowing assay of either citrated or heparinized samples. A 100 ml plasma sample was pre-warmed at 37°C and 50 ml of enzyme was added to initiate clotting. A standard clotting curve was obtained from normal plasma. Fibrinogen was measured in pre-column and post-column samples. For all these coagulation assays, a semi-automated coagulation instrument (ST4, Diagnostica Stago, Parsipanny, NJ, USA) was used to measure clotting times.
Complement activation
The ELISA test from Research Diagnostics (Flanders, NJ, USA) was used to measure the level of C3a-desArg in pre-and post-column plasma samples.
Statistical analysis
Numerical data were analyzed by using Student's t-test. A P-value < 0.05 was considered statistically significant.
RESULTS
Assessment of the stability of the Ofloxacin resin
First, it was verified that Ofloxacin was not leaching from the column by running LAL water and measuring the absorbance at 286 nm, the wavelength for maximum absorbance of Ofloxacin. The OD of the flow-through was compared to the OD generated from an Ofloxacin standard curve (0.15-10 mg/ml), and was below the detection limit of a solution of 0.15 mg/ml. Moreover, the addition of Ofloxacin at 1 mg/ml in spiked plasma had no effect on the endotoxin measurement by the LAL assay, performed by diluting and heat inactivating the plasma. The removal of endotoxin was also as efficient in the presence of free Ofloxacin added to the plasma (data not shown). These results indicate that, at the concentration tested, Ofloxacin is not affecting the removal or the measurement of endotoxin in plasma.
Validation of the LAL assay for comparison of endotoxin levels in pre-and post-column plasma samples
In order to quantify accurately the endotoxin levels in pre-and post-column samples, endotoxin recovery was assessed and compared in these samples. The presence of inhibition or enhancement in pre-and post-column plasma was determined by adding known amounts of endotoxin from P. maltophilia or purified E. coli O55:B5 endotoxin to these unspiked samples. After spiking with endotoxin, the samples were diluted 10 times and heatinactivated at 75°C for 15 min. Endotoxin measured in LAL water using endotoxin from E. coli O55:B5 as control standard and P. maltophilia culture supernatant at various dilutions were not significantly different. There was also no significant difference between the recoveries in pre-column plasma (110 ± 11%; average ± SD of the 4 concentrations tested) and post-plasma (110 ± 13%; average ± SD of the 4 concentrations tested) samples for P. maltophilia using Student's t-test. Therefore, it was possible to use E. coli O55:B5 control standard endotoxin to generate a standard curve in the LAL assay and to quantify P. maltophilia in plasma, diluted 10 times and heat inactivated. The assay was also accurate to compare endotoxin levels in pre-and post-column plasma samples to assess endotoxin removal. Some experiments were performed by diluting the plasma samples 67 times followed by heat inactivation, and the same conclusion could be drawn. Purified endotoxin from E. coli O55:B5, S. typhimurium, P. aeruginosa, or E. coli O55:B5 culture supernatant recoveries were also not statistically different in pre-and post-column plasma (data not shown).
Endotoxin removal from plasma as measured by LAL assay
This paper describes the removal of endotoxin from human plasma. The removal of endotoxin was performed in a dynamic setting. Plasma spiked with endotoxin circulated through a 1.5 ml column packed with affinity resin. We first used a supernatant of P. maltophilia, a Gram-negative bacteria, as a model to spike plasma and challenge the adsorbent. We chose to spike the plasma with endotoxin levels between 1-5 EU/ml; this amount of endotoxin is representative of levels in the blood of septic patients. 30, 42 A cross-linked agarose gel without Ofloxacin was used as a control resin. In this setting, the P. maltophilia endotoxin removal on the Ofloxacin resin was statistically significant with P < 0.01 for all time points. This affinity resin was able to remove 53.4 ± 6.9% (average ± SD of 5 time points) of the loaded endotoxin (Fig. 1A ). This removal efficiency was similar when the samples were diluted 67-fold and heat inactivated, independently of the initial endotoxin content of the plasma. On average, 51% of 1.35 ± 0.12 EU/ml, as measured by the LAL assay, was removed over 20 min, and 47% of 2.5 ± 0.18 EU/ml was removed over the same period. The agarose cross-linked control resin did not significantly remove P. maltophilia endotoxin (Fig. 1C) . The efficiency of removal of the Ofloxacin resin was compared with that of a PMXB resin. Using our assay, a significant removal of P. maltophilia endotoxin could be measured only for two time points tested. At 11.5 and 20 min, 7.4% (P < 0.001) and 19.8% (P = 0.006) of the pre-column endotoxin could be removed, respectively (Fig. 1B) . During 20 min, 12 ml of plasma circulated on a 1.5 ml column and the efficiency of P. maltophilia endotoxin removal by the Ofloxacin resin did not significantly decrease with time. Therefore, the Ofloxacin column is able to remove P. maltophilia endotoxin from 8 bed volumes of plasma with about 50% efficiency. A separate experiment indicated that this efficiency is maintained for at least 40 min (data not shown). On this basis, the volume of plasma for Removing endotoxin from plasma using hemocompatible affinity chromatography technology 89 Fig. 1 . P. maltophilia endotoxin removal from plasma by adsorption through a 1.5 ml column. Samples were collected at various times using sterile needles and syringes via a sample port. Endotoxin levels in plasma in pre (solid line) and post-column (dashed line) were determined by the LAL assay after a 1:10 dilution of the samples and heat inactivation at 75°C for 15 min. Endotoxin removal was performed on an Ofloxacin resin (A), PMXB resin (B) and an agarose resin (C). The results are expressed as average ± SD from 2 replicates from a representative experiment. For all time points, P < 0.01 (Student's t-test) (A). On the PMXB resin (B), a significant difference between pre-and post-column endotoxin levels was measured at 11.5 min (P < 0.01) and at 20 min (P = 0.006). an average adult being 2.5 l, a column of about 150 ml would be sufficient to treat the entire volume of plasma. Therefore, it is noteworthy that the extracorporeal volume in a scale-up device would be reasonably low.
In order to test whether this resin can remove endotoxin produced by other bacterial species as well as purified endotoxin, endotoxin from E. coli O55:B5, either lyophilized or from a culture supernatant was used to spike plasma. Purified P. aeruginosa and S. typhimurium endotoxin were also tested. Endotoxin from all bacterial sources was bound by the Ofloxacin column, although with different efficiencies (Table 1) . Nevertheless, the Ofloxacin resin displays a broad affinity for various endotoxin.
Endotoxin removal from plasma as measured by monocyte activation assay
In order to demonstrate that the removal of endotoxin had physiological significance, a biological assay was used. The monocyte activation assay, which represents the in vitro equivalent of the rabbit pyrogen test was employed. Monocytes, when exposed to pyrogenic substances, secrete inflammatory cytokines (IL-1, IL-6, IL-8, TNF-a, etc.) that can be detected at very low levels. Induction of TNF-a secretion by monocytes was, therefore, used as an in vitro assay system for endotoxininduced inflammatory reactions. When monocyte activation was employed as a measurement of endotoxin removal, plasma was spiked with 200 EU/ml of endotoxin, since lower amounts under these specific experimental conditions did not generate significantly higher cytokine production than unspiked plasma. In preliminary experiments, TNF-a production by monocytes induced by known amounts of LPS in water, pre-and postcolumn plasmas were compared. The results indicate an inhibitory effect of plasma on TNF-a production, previously reported by others. 20, 43, 44 LPS-binding proteins present in plasma have been shown to inhibit LPS activity in vitro and in vivo. 41, [45] [46] [47] However, pre-and post-plasma spiked with the same amounts of endotoxin generated nonstatistically different TNF-a measurement ( Fig. 2A) . TNFa secreted by monocytes was significantly decreased by 60-98% depending on the time of collection (P < 0.01) when plasma was run through the Ofloxacin affinity column. In such cultures, endotoxin removal as measured by the LAL assay, was accompanied by a decrease in TNF-a production for the duration of the experiment (30 min; Fig.  2B) . The TNF-a content in the conditioned media was lower in the first two samples. This may reflect an initially more efficient pyrogen removal. The Ofloxacin affinity resin was then able to reduce the TNF-a produced by the endotoxin-spiked plasma by 68%. The fact that the TNF-a production is not linearly correlated to the amount of LPS 90 Amoureux, Hegyi, Le, Grandics, Tong, Szathmary Plasma was spiked with endotoxin and run through the column at 0.6 ml/min. Samples were collected pre-and post-column to determine the endotoxin content by the LAL assay after a 1:10 dilution and heat inactivation at 75°C for 15 min. The results are expressed as percentage removal of loaded endotoxin. introduced ( Fig. 2A) does not allow us to deduce accurately the amount of pyrogen removed under the conditions of this assay. Nevertheless, it can be estimated that the Ofloxacin resin removed more than 75% of the TNF-a inducing components present in the P. maltophilia supernatant.
Demonstration of absence of activation of coagulation by the affinity resin
Possible changes in hemostasis during perfusion of the plasma through the endotoxin removing resin may affect the patients, especially those who are severely ill, and who already experience coagulation abnormalities because of septic shock. We, therefore, asked whether the resin was hemocompatible and evaluated its effect on plasma hemostasis. First, we analyzed the effect of the resin on the activation of coagulation. Any thrombin produced as the result of activation of the coagulation cascade, is rapidly inactivated by antithrombin (AT) to form TAT complexes in the presence of heparin. This provides a sensitive and specific means to detect evidence of activation of the coagulation cascade. The level of TAT remained unchanged after the plasma circulated through the endotoxin removing resin. Pre-column TAT level was 0.172 ± 0.005 mM and the TAT level in post-column sample was 0.165 ± 0.004 mM (average ± SD of 4 time points over 10 min). The level of TAT was minimal compared to the normal level of AT in plasma (5 mM AT). These results indicate that the affinity resin does not elicit coagulation of the plasma.
Demonstration of absence of consumption of coagulation factors
To further characterize the hemocompatibility of the endotoxin removing resin, the possible binding of coagulation factors to the resin was investigated by PT and APTT assays. No significant change in PT was indicative of absence of consumption of any of the following factors: Factor II, Factor VII, Factor X or Factor V (Fig. 3) . Similarly, no consumption of Factors XII, XI, IX, VIII, V, X, II, prekallikrein or high molecular weight kallikrein occurred as APTT values remained normal, about 33 s in all post-column samples (Fig. 3) . These findings support the conclusion that coagulation factors do not bind to the affinity resin, underlying its specificity for endotoxin.
Demonstration of no loss of fibrinogen
Fibrinogen is used to form the fibrin clot catalyzed by thrombin in vivo. Fibrinogen concentration was measured in pre-and post-column plasma samples. Atroxin was used as an alternative to thrombin to catalyze the formation of fibrin from fibrinogen since it is insensitive to heparin, thus allowing the assay of either citrated or heparinized samples. Fibrinogen levels remained between 85-100% (of pre-column value) in post-column samples and were not statistically different than pre-column plasma fibrinogen content (Fig. 4) .
Demonstration of absence of complement activation
C3a is generated during the activation of the complement system via the classical or the alternative pathway. It is an early component of the complement activation. C3a itself is very short lived and is immediately cleaved into the more stable C3a-desArg. Therefore, quantitation
Removing endotoxin from plasma using hemocompatible affinity chromatography technology 91 of C3a-desArg allows reliable measurement of the level of complement activation. At 15 min after the initiation of the circulation, a slight increase appeared to occur in the post-column sample. However, this was not observed in other samples, where C3a-desArg was not statistically different in post-column samples compared to pre-column samples (Fig. 4) . C3a-desArg remained in the normal range of 210 ng/ml. These data suggest that the resin does not trigger significant complement activation.
DISCUSSION
This paper describes a potential treatment for one of the most complex, challenging and devastating diseases of our time. The incidence of sepsis is projected to increase 1.5% per year, yielding 1,110,000 cases by the year 2020. 1 Decades of research to overcome septicemia or even decrease the mortality rate have been unsuccessful, costly and disheartening. Extracorporeal strategies such as continuous renal replacement therapy or therapeutic plasmapheresis have shown benefit on hemodynamics and survival in uncontrolled sepsis trials or animal models. 17, [48] [49] [50] [51] Plasmapheresis or therapeutic plasma exchange has been used since 1978 for the removal of different proteins from plasma. This method primarily causes a rapid depletion of proteins in the range of 67-2400 kDa such as antibodies, immunecomplexes or alloantigens. 52 Therefore, the limitations are evident due to the lack of specificity of removal of pathognomic and toxic substances from the blood. The need for specific removal of substances implicated in septic shock has been recognized. 17, 42 The endotoxin theory in Gram-negative septicemia has been extensively explored, and results show that once the cascade of endotoxin, CD14, pro-inflammatory proteins and cytokines has been set in motion, further active downstream substances are produced and contribute to the irreversible chain of events characteristic of the pathophysiology.
In this paper, adsorption of endotoxin from plasma was described using an affinity resin which basis is agarose beads and an endotoxin specific ligand, Ofloxacin. The removal of endotoxin from P. maltophilia present in amounts typically found in septic patients' blood was achieved with 50% efficiency on more than 10 column-bed volumes of plasma. Moreover, this resin was able to remove endotoxin produced by other bacterial species, with an efficiency of 17.2-43.9%. Variable structures and aggregation states of endotoxin are likely to affect the removal efficiency. While monomers of endotoxin have a molecular weight of 10-20 kDa, endotoxin forms aggregates of 200-1000 kDa. 53, 54 Since chromatography is partly dependent on size exclusion phenomenon, the aggregation state of endotoxin is likely to influence the removal efficiency. Large aggregates limit the accessibility of endotoxin to the immobilized ligand. The aggregation state of endotoxin is known to be different in size and mass between different bacterial species, which may partly explain the different removal efficiencies for different endotoxin. 55 LPS from different sources display different critical aggregation concentrations. 56 The direct measurement of endotoxin decrease was concomitant with a decrease in TNF-a production by monocytes exposed to plasma that had been run on the Ofloxacin column. TNF-a production is an important early host responses to endotoxin contamination and is involved in the inflammatory response in sepsis. TNF-a is induced in vitro by endotoxin challenge and can also induce the production of IL-1 in various cell types, as well as IL-6. 57 TNF-a is capable of triggering the entire spectrum of metabolic, hemodynamic, tissue and cytokine responses of septic shock. 58 Since other bacterial components can induce TNF-a, the removal of other types of pyrogens from P. maltophilia culture supernatant may also have occurred. The reduction of TNF-a inducing activity from the spiked plasma was maintained with durable efficacy over 20-30 min, the maximum time consistently tested. These data are strongly indicative that the circulation of plasma through the affinity resin results in a beneficial physiological response in blood cells exemplified with a reduction of activation of monocytes. Technologies aiming at removing toxins, including endotoxin, have been described but present limitations. The efficiency of some of these methods such as the Biologic-Detoxification System sorbent-based apheresis 60 is inferior to the efficiency of our system. Cation exchangers have moderate affinity for negatively charged LPS at physiological pH. 59 Endotoxin removal by human serum albumin coated on acrylic beads was not demonstrated for levels relevant to those found in septic patients. 60 The hemoperfusion method using PMXF was evaluated in a multicenter clinical study. Of 42 patients, 52% survived at day 14 after PMXB treatment. 42 However, it has also been shown that PMXB removes only some, but not all, endotoxin from solutions. 61 In addition, the endotoxin-binding capacity of PMXF was not as efficient as the device presented in our study, with a reported decrease of 11% (pre-column endotoxin, 129 ± 140 pg/ml; post-column endotoxin, 115 ± 127 pg/ml) 62 or 18.5% (pre-column endotoxin, 27 ± 2.2 pg/ml; post-column endotoxin, 22 ± 2.7 pg/ml) 42 in post-column values compared to pre-column. These results are comparable those we obtained when we tested beads coupled to PMXB. It is possible that the precision of measurement by the LAL assay in this study did not allow measurement of significant differences between pre-and post-plasma samples for all time points; however, even for the time points where a significant removal was measured, the Ofloxacin resin displays higher removal efficiency than the PMXB resin. The fairly low efficiency of endotoxin binding by PMXF may explain why PMXF failed to reduce systemic plasma endotoxin during endotoxemia in anesthetized sheep. 35 Nevertheless, the systemic endotoxin level was considerably reduced 1-2 days after PMXF treatment in human trials. [63] [64] [65] The use of natural and synthetic cationic peptides has also been suggested, 66 and appears an attractive approach, but only limited amounts can be isolated from the host species and peptide technology is expensive when scaled-up.
The absence of activation of coagulation and of the complement system along with the absence of loss of coagulation factors and fibrinogen also revealed the inert properties of the endotoxin-removing resin regarding hemostasis. Unpublished data on prolonged experiments suggest that even larger volumes of plasma may be processed without affecting hemostasis or activating complement. Other endotoxin-removing methods are also mostly non-specific and this lack of specificity may affect plasma hemostasis. The Biologic-Detoxification System sorbent-based apheresis removes cytokines but not endotoxin. 59 Polyanion-modified support material for the extracorporeal adsorption of TNF-a and LPS from whole blood and/or plasma is not specific for endotoxin. 67 Von Appen et al. 68 also reported data on removal of endotoxin, bilirubin, tryptophan and digitoxin, collected by the use of a microsphere-based detoxification system (MDS). The system consists of cellulose microspheres of less than 20 mm in diameter, packed into a fluidized bed device, and attached to a plasmapheresis circuit. In addition to charcoal and bilirubin adsorbers, plasma circulates through ion exchange adsorbers to remove endotoxin. The mechanism of binding between the microspheres and molecules is based on electrostatic rather than biospecific interactions. The molecular adsorbent recycling system (MARS) is a high flux dialysis treatment method for removing protein-bound toxins from plasma (bilirubin, tryptophan and digitoxin). Major technical parameters of MARS are HF80 polysulfone membrane and activated charcoal and bilirubin adsorber as in the MDS system. 68 Such anion-exchanger resins may also bind and remove coagulation factors, and other important proteins from the plasma, which may lead to clinical complications. Zimmerman et al. 60 reported the use of the non-specific adsorbent human serum albumin coated on acrylic beads. Technologies such as heparininduced extracorporeal lipoprotein fibrinogen precipitation (HELP) remove endotoxin as well as C-reactive protein, TNF-a, apoB, fibrinogen and cholesterol. 69 Therefore, the adsorption of endotoxin by currently available adsorbers has limitations with regard to efficiency, specificity and cost-effectiveness. In addition, the biocompatibility of the majority of these surfaces has not been examined. The technology presented here utilizes a large particle of agarose-based support that has high binding capacity and allows the free passage of cells between the particles. We have demonstrated that this new method represents an efficient, specific and hemocompatible method to remove endotoxin from plasma. The efficiency of binding of the resin suggests that a minimal extracorporeal volume of blood would be required to be processed. The removal of endotoxin from plasma or whole blood in an extracorporeal setting could improve the outcome of sepsis. The potential benefit of endotoxin removal is maintained through all phases of the disease: in the very early phase of the septic syndrome, where removal of endotoxin may prevent the development of septic shock, as well as in the late clinical stage of immunoparalysis, in which the patients are defenseless against new infections and response less to new triggering factors due to the exhaustion of their immune system. Inasmuch as endotoxin participates in both the inflammatory and coagulation abnormalities in sepsis, this approach may prove particularly beneficiary. Opal et al. 30 found that survivors of septic shock had, on average, 2-fold less endotoxin than non-survivors in the systemic circulation at the onset of severe sepsis and septic shock. The median level endotoxin level in survivors was 230 pg/ml and the median level for non-survivors was 515 pg/ml. Although this level may vary during the course of the septic episode and this is not directly indicative of the clinical benefit of endotoxin removal, the difference between survivor and non-survivor levels is within the range of reduction achieved by our device. Tani et al. 62 also found that lower levels of endotoxin were present in survivors after PMXF treatment. Therefore, it is reasonable to suppose that higher removal efficiency by the Ofloxacin resin may result in clinical benefit. Because of the complexity of the pathology and the numerous factors involved, it is likely that a multitarget approach will be necessary to considerably increase survival in sepsis. Endotoxin removal could be useful by itself or as part of a multimodal treatment of sepsis.
This study provides the basis for further investigations that could have an important clinical benefit to treat plasma and potentially whole blood from septic shock patients.
